SCHEMBL17997163

SCHEMBL17997163

CCCC(C)Sc1nnnn1-c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 16/20 0.60
▸ KMT2A Q03164 3/20 0.53
▸ TP53 P04637 2/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ LMNA P02545 8/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ TSHR P16473 2/20 0.51
▸ HPGD P15428 1/20 0.51
▸ MAPT P10636 4/20 0.50
▸ HTT P42858 3/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ POLB P06746 2/20 0.49
▸ RECQL P46063 1/20 0.47
▸ TDP1 Q9NUW8 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46
▸ RELA Q04206 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14288405 0.87 ALDH1A1 (0.56) ALDH1A1KMT2ATP53MEN1LMNA
SCHEMBL10731214 0.84 ALDH1A1 (0.62) ALDH1A1KMT2ATP53MEN1LMNA
SCHEMBL5962424 0.82 ALDH1A1 (0.66) ALDH1A1KMT2ATP53MEN1LMNA
SCHEMBL10478322 0.81 ALDH1A1 (0.54) ALDH1A1KMT2ATP53MEN1LMNA
SCHEMBL19824601 0.79 ALDH1A1 (0.50) ALDH1A1KMT2ATP53MEN1LMNA
SCHEMBL1710000 0.78 ALDH1A1 (0.61) ALDH1A1KMT2ATP53MEN1LMNA
SCHEMBL8827913 0.75 ALDH1A1 (0.70) ALDH1A1KMT2ATP53MEN1LMNA
SCHEMBL9803958 0.75 ALDH1A1 (0.58) ALDH1A1KMT2ATP53MEN1LMNA
SCHEMBL10448232 0.75 ALDH1A1 (1.00) ALDH1A1KMT2ATP53MEN1LMNA
SCHEMBL11749330 0.74 ALDH1A1 (0.77) ALDH1A1KMT2ATP53MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180028509-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-02-01 — — US disclosed
US-9861620-B2 Substituted quinolizine derivatives useful as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2018-01-09 — — US disclosed
US-20160228419-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228419-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS NQO2, CYP3A5, QTRT1 ALDH1A1 1564/4885KMT2A 839/4885TP53 1690/4885
US-20180028509-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS NQO2, CYP3A5, QTRT1 ALDH1A1 1564/4885KMT2A 839/4885TP53 1690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback